BioSpace News Archive

QYNAPSE SAS, a medical technology company, will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease Conference.

For the first time, Canadians will have access to at-home HIV self test kits. bioLytical Laboratories, a world leader in rapid infectious disease tests, announced that it has received Health Canada Licence to produce and sell its highly accurate, 1-minute INSTI® HIV Self Tests in Canada.

Viseon, Inc., a leader in minimally invasive spine visualization technologies, announced use of its new miniature camera system, MaxView™, for single position prone XLIF® surgery.

The global advanced wound care management market is anticipated to experience substantial growth owing to several research and development based activities taking place through intensive efforts made by well-established competitive players.

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP).

The demand within the global market for ambulatory services has been rising on account of the growing sophistication of the global healthcare industry.

The proliferating use technology for everyday functioning, including health and fitness is paving immense opportunities for the mindfulness meditation apps market.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the use of the ORAcollect®·RNA (OR/ORE-100) saliva collection device for the collection, stabilization and transport of saliva specimens suspected of containing SARS-CoV-2 RNA.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has entered a royalty monetization agreement with an affiliate of Marathon Asset Management, a leading global investment firm (“Marathon”)